Background. Recombinant tissue-type plasminogen activator (rt-PA or alteplase) and anisoylated plasminogen streptokinase activator complex (APSAC or anistreplase) have been demonstrated to limit infarct size significantly and to preserve left ventricular function when injected soon after acute myocardial infarction. However, as yet, the efficacy and safety of these two thrombolytic agents have not been directly compared in one trial; this was the aim of this study.
frequency of bleeding complications, and more specifically intracranial bleeding complications, has been observed with both drugs.71'015
These two drugs have not as yet, to our knowledge, been directly compared in one trial. Hence, the aim of our study was to assess the safety and efficacy of these two drugs in recent acute infarction, taking into account clinical tolerance and the effects on infarct size and left ventricular function. These two end points are essential in evaluating the efficacy of thrombolytic therapy in acute recent myocardial infarction.
Methods

Design of the Study
A multicenter randomized trial was conducted at 24 hospitals in French provinces: three university hospitals, one nonuniversity hospital, and 21 affiliated community hospitals without catheterization facilities. Any patient less than 70 years old suffering from a first acute transmural myocardial infarction and referred to any one of these hospitals within 4 hours of the onset of symptoms was eligible for randomization. Criteria used for the initial diagnosis of evolving myocardial infarction were: a minimum 2-mm ST segment elevation in at least two leads with or without Q waves uninfluenced by 0.4 mg sublingual nitroglycerin. Exclusion criteria were 1) chest pain lasting less than 20 minutes or relieved by sublingual nitroglycerin, 2) a recent history of stroke, surgery, or trauma, 3) a predisposition to bleeding, 4) a history of previous myocardial infarction with proven preexisting Q waves in at least two adjacent leads, 5) coronary artery bypass surgery, 6) cardiogenic shock defined as systolic blood pressure below 80 mm Hg unresponsive to rapid infusion of plasma and/or to a 0.5-mg i.v. injection of atropine sulfate, 7) effective oral anticoagulant therapy at admission, 8) permanent severe systemic hypertension, 9) an ongoing gastroduodenal ulcer, or 10) recent external cardiac massage. After informed consent, patients were allocated to either APSAC or rt-PA according to a double-blind-double-dummy procedure. In the first arm of the trial, called the APSAC group, patients successively received a bolus injection of a heparin placebo, a single injection of 30 units APSAC over 5 minutes, and an injection of a placebo rt-PA given over 180 minutes after an initial bolus injection. In the second arm of the trial, called the rt-PA group, patients successively received a bolus injection of 5,000 units heparin, a placebo APSAC given over 5 minutes, and 100 mg of rt-PA (singlechain rt-PA) over a 180-minute period with an initial 10-mg bolus initial injection. Heparin was reintroduced in both groups 4 hours after initial therapy at a dosage of 1,000 units/hr. This was maintained for at least 7 days, after which acenocoumarol was introduced. All patients were given a 250-mg dose of aspirin orally as soon as the diagnosis of acute myocardial infarction was ascertained. The initial dose was repeated daily. /3-Blockers were not mandatory during the first 6 hours of evolution except in patients treated with such agents before entry in the trial. This was to prevent the potential protective effects of these agents on the ischemic myocardium from interfering with the salvaging effects of early reperfusion, this being the purpose of this trial. The decision for any other medication or procedure, as required by a patient's condition, was left to the initiative of the attending physician.
Electrocardiogram recordings were made on admission, at 6 hours and 24 hours after initial therapy, and whenever there was a recurrence of chest pain. Standard laboratory tests including a complete blood count, creatine kinase-MB isoenzyme, fibrinogen level, and activated partial thromboplastin time were also made on admission and 6 hours and 24 hours after the initiation of therapy. Coagulation tests were repeated once or twice daily after the first 24 hours of evolution in order to adapt the anticoagulant therapy.
Posttherapy Procedures
Following initial therapy, patients were referred to the university hospital of the respective province. Here, they were subjected to coronary angiography and left ventricular angiography within 7 days of the onset of symptoms. Within the third week, radionuclide angiography and single-photon emission computerized tomography were performed according to protocols described in detail elsewhere. 16 Briefly, coronary arteriography was performed using the femoral percutaneous approach. Multiple views of the right and left coronary systems were obtained in right and left anterior oblique positions with at least two orthogonal views for each coronary system, before and after a 3-mg intracoronary injection of isosorbide dinitrate. Angulated craniocaudal views were used as well. Two independent experienced angiographers, working separately and blindly, analyzed all coronary angiograms from each of the university centers. They were asked to quantify the severity of stenosis of both the infarct-related artery and noninvolved arteries for all angiograms. The severity of stenosis was subjectively assessed according to a five-grade scoring system: 0, occlusion; 1, 95% lumen obstruction with delayed runoff of dye distal to the lesion; 2, 95% lumen obstruction without delayed runoff of dye; 3, 75-95% lumen obstruction; and 4, less than 75% lumen obstruction (nonsignificant lesion). The infarct-related artery was considered to be occluded if graded 0 or 1 and patent if graded 2 or more. When discrepancies arose between the two observers, the principal investigator intervened and classification was reached by consensus.
Biplane left ventricular angiography was performed in each patient in a 300 right anterior oblique position and a 600 left anterior oblique position. Left ventricular volumes and ejection fraction were determined from the 300 right anterior oblique left ventricular angiography. Regional wall motion was analyzed according to Leighton's method,17 from which a regional semiquantitative asynergic score was derived according to a method described in detail in a previous study. 16 Briefly, after the left ventricular end-systolic frame was superimposed onto the left ventricular end-diastolic frame to realign both long axes, 10 anterior hemiaxes and 10 inferior hemiaxes were then drawn perpendicular to the end-diastolic long axis. The 20 hemiaxes were given scores according to the magnitude of the fractional shortening measured on each of them: 0, fractional shortening within the normal range (estimated from the left ventricular angiogram of 30 patients with chest pain and normal coronary arteries and considered normal); 1, fractional shortening between -2 SD from normal and 20% shortening; 2, fractional shortening between 20% and 5%; and 3, fractional shortening less than 5% including negative values. A semiquantitative asynergic score was obtained by adding the values of all hemiaxes of the infarcted area showing an abnormal contraction pattern. All left ventricular angiograms of each of the three centers were blindly processed at one center by two independent angiographers. The average value of each determination was used for statistical analysis of results. In this study, the 95% confidence intervals of the intraobserver and interobserver absolute differences (mean±2 SD) were (-3%; +3%) and (-4.1; +3.9%), respectively.
For the isotopic studies, the cameras and computers used at each university center in this trial were of the same trademark and model. The acquisition of data at all three centers was performed using the same labeling and the same computer programs to guarantee uniform and consistent data.
Myocardial scintigraphy was performed with a 1.1 mBq (30 ,uCi)/kg dose of thallium-201 chloride injected with the patient at rest in a seated position. Ten minutes later a single-photon emission computerized tomography acquisition was started using a rotating large-field scintillation camera equipped with a low energy-high resolution collimator. Spectrometry was set with a 25% window over the 69-83 keV x-rays and with a 15% window over the 167 keV gamma rays of thallium-201. Thirty-two 30-second views were collected during a 1800 rotation of the camera head between the left posterior and right anterior oblique positions. Each position was stored as a 64 x 64 matrix in a dedicated computer. All thallium-201 studies from each university center were processed independently in one center by two observers blinded to the patients' treatment. Adjacent one-pixel-thick transverse sections were reconstructed using a backprojection algorithm with a pure ramp filter. Sagittal sections were then obtained. Both series were smoothed with a tridimensional filter. Defect size was measured on the most appropriate seriestransverse sections for anterior and lateral infarcts and sagittal sections for inferior infarcts. The limits of the normal myocardium were outlined by thresholding with a line of isoactivity corresponding to 35% of the highest activity in the total myocardium. The limits of the defect were drawn manually by interpolating between its endocardial and epicardial borders. Normal muscle and RNA LAO VIEW EF in 11 ANGULAR SECTORS 5 to 8 SEPTAL ZONE 9 to 11 APICO-INF. ZONE 12 to 15 LATERAL ZONE 3 4 FIGURE 1. Drawing representing left anterior oblique (LAO) radionuclide angiography (RNA) view of left ventricle with 11 angular sectors from which regional ejection fraction was estimated. Sectors 5-8 represent septal region, sectors 9-11 apical region, and sectors 12-15 lateral region of left ventricle. Sectors 1-4 and 16 represent mitral and aortic area and are not considered for evaluation of regional wall motion. EF, ejection fraction. defect volumes were calculated by summation of the number of pixels belonging to the normal myocardium and to the defect on all the sections passing through the myocardium. Infarct size was expressed as a percentage of the total myocardial volume. This method has been shown to allow accurate determination of infarct size in laboratory animals.18 In clinical practice, the 95% confidence intervals of the intraobserver and interobserver absolute differences (mean±2 SD) were (-3%; +3%) and (-4.1%; +3.9%), respectively.
Immediately after completion of the thallium-201 acquisition, each patient was injected with a 74 mBq (20 mCi) dose of technetium-99m human serum albumin. Sixteen 64x64 frames were collected in the left anterior oblique position. All radionuclide studies from each university center were processed at one center other than the thallium-201 processing center. Two independent observers worked separately, blinded to the patients' treatment. A routine semiautomatic method using two left ventricular regions of interest was used to calculate the global left ventricular ejection fraction. Regional ejection fractions were assessed on 16 angular sectors. Sectors 5-8 represented the septal region, sectors 9-11 the anteroapical region, and sectors 12-15 the lateral region of the left ventricle. Sectors 1-4 and 16 were not taken into account as they represent the mitral and aortic valve areas16,20 ( Figure  1 ). With this technique, the 95% confidence intervals of the intraobserver and interobserver absolute differences (mean±2 SD) were (-2.8%; + 2.6%) and (-3%; +2.8%), respectively.19 Sample Size
In a previous study we compared the efficacy of APSAC with that of conventional heparin therapy in recent (less than 5 hours) evolving infarction. In this first study, which altogether included 231 patients and used the same design and protocol, we found a significant improvement in favor of APSAC-treated patients in all of the three following variables (twotailed test): left ventricular ejection fraction deter- mined from contrast angiography was 0.47±+0.11 in the heparin group and 0.53±0.11 in the APSAC group, asynergic score was 14±9 in the heparin group and 9.5+6 in the APSAC group, and infarct size was 19+13% in the heparin group and 13+11% in the APSAC group. 16, 20 The hypothesis in the present study was to detect a difference between the tuo tested drugs of 0.05 or more for contrast left ventricular ejection fraction, of 3.5 or more for asynergic score, and 5% or more for infarct size, with a first-kind error (or a error) of 0.05, and a second-kind error (or error) of 0.10.
Using the standard deviations observed in the above-mentioned trial,16 and according to the hypothesis of a two-sided test, at least 89 patients were needed in each arm of the trial to demonstrate such a difference. Hence, it was decided to limit the inclusions to 180 patients.
Statistical Analysis
Student's t test was used to compare the quantitative variables, the x2 test to compare the qualitative variables, and single linear regression analysis to estimate the relation between infarct size and left ventricular ejection fraction. All values were expressed as mean plus standard deviation.
Results
All data were analyzed according to the intentionto-treat principle.
Population
From May 15, 1988 to July 30, 1989 , 183 patients were recruited (see Table 1 ). A total of 90 received APSAC and 93 received rt-PA. The average age, sex ratio, time of randomization, location of infarction, and functional status at admission were similar in both groups. There was no difference in the patients' treatment before entry in the trial. Fifteen APSAC In-Hospital Clinical Course Heart failure estimated according to Killip classification was of the same intensity and same frequency in both groups (see Table 2 ). Similarly, the frequency of reinfarction (defined as recurrence of symptoms with new ST segment elevation of 2 mm or more in the leads exploring the infarcted region and/or increase of creatine kinase levels more than twice the upper limit of normal), the frequency of ventricular premature beats, the frequency of ventricular tachycardia (more than five ventricular premature beats in a row), and the frequency of ventricular fibrillation were not significantly different in the two treatment groups.
Twelve patients died during the in-hospital phase. Five patients (5.5%) in the APSAC group died, one on day 18 of a proven ischemic cerebrovascular accident that had occurred on day 13. Seven patients (7.5%) in the rt-PA group died, including one who died of intracranial hemorrhage 12 hours after the initiation of therapy. This fatal intracranial hemorrhage occurred in a 65-year-old female patient admitted within 3 hours of the onset of symptoms. Her fibrinogen level was 0.20 g/l and the activated partial thromboplastin time was above 150 seconds when the neurological disorder occurred. She weighed 48 kg, so the total dose of rt-PA actually injected into this patient amounted to 2 mg/kg of body weight. After discussion, the trial's steering committee decided to modify the inclusion criteria by excluding patients weighing less than 65 kg from the trial.
Adverse Effects
The side effects observed in both patient groups are summarized in Table 3 . The overall bleeding complication rate, including hematoma at groin puncture site, was equivalent in both therapeutic groups. Eleven APSAC patients (12.2%) suffered from bleeding, seven of them within 24 hours after drug administration. In each of the seven patients, fibrinogen level decreased to below 1 g/l. Nine rt-PA patients (9.6%) suffered from bleeding, six of them within 24 hours after drug administration, and three patients out of six had fibrinogen levels below 1 g/l. Bleeding complications requiring transfusion were observed in one APSAC patient (fibrinogen level 0.09 g/l, 6 hours after drug administration) and two rt-PA patients (fibrinogen level 0.10 and 0.30 g/l at 6 hours after drug administration). All in all, lifethreatening bleeding, defined as either visceral bleeding requiring blood transfusion or intracranial bleeding, occurred in one APSAC-treated patient (1.1%) and in three rt-PA-treated patients (3.3%).
Three cerebrovascular accidents were observed in the overall study group. Two ischemic episodes occurred in the APSAC group. In one patient, a monoplegia occurred 5 hours after the onset of therapy and regressed within 3 days. Two-dimensional echography showed an apical thrombus of the left ventricle. Subsequently, the patient suffered a wall rupture, which rapidly led to death on day 8. Left ventricular free wall rupture and ischemic brain damage were confirmed at the postmortem examination. In the second patient, a cerebrovascular accident occurred on day 13 after the onset of therapy. In this case, mentioned previously, the patient died 5 days later of irreversible ischemic brain damage. In both of these cases, evidence of the ischemic cause for the neurological disorder was given by CT scan. One neurological episode, also previously mentioned, occurred in the rt-PA group: In this case, a sudden coma with bilateral mydriasis occurred 12 hours after the onset of therapy and led to death within a few minutes, thus precluding CT scan. The clinical aspect of the neurological disorder in this last case was compatible with a hemorrhagic process. Fibrinogen level was 0.20 g/l at 6 hours after start of therapy. No postmortem examination was performed.
Hypotension after injection of the tested drugs (defined as at least 30 mm Hg systolic blood pressure drop occurring within 30 minutes after the administration of the drug and lasting at least 15 minutes) was similarly frequent in both therapeutic groups. In each case, hypotension resumed after discontinuation of nitrates. In no case was volume expansion necessary.
Coronary Angiography
Coronary angiography was obtained in 169 patients (85 APSAC patients, 94%, and 84 rt-PA patients, 90%) on average 5.3+2.2 days after the initiation of therapy in the APSAC group and 5.4±2.4 days in the rt-PA group (NS) (see Table 4 ). Coronary angiography was not performed in nine patients who died before the investigation and in five who refused it. Missing data were equally distributed in both therapeutic groups. The infarct-related artery was patent in 61 APSAC patients (72%) and in 64 rt-PA patients (76%) (NS). The distribution of single-, double-, and triple-vessel disease was similar in both therapeutic groups. Conversely, the distribution of the infarctrelated artery was not exactly equivalent in both therapeutic groups. Although the difference failed to reach statistical significance, it is worth noting that the proximal left anterior descending artery was more often involved in the APSAC group than in the rt-PA group in the case of anterior infarction (17 cases, 20% versus 13 cases, 15.4%).
Revascularization Procedures
Immediate angioplasty of the infarct-related artery was attempted in 27 APSAC-treated patients (32%) and successful in 23 (27%). It was attempted in 29 rt-PA-treated patients (34%) and successful in 24 (28%). Coronary artery bypass surgery was performed on three APSAC patients and two rt-PA patients during the in-hospital phase. Coronary angioplasty was performed only in the presence of suitable anatomy of the infarct-related artery and preserved wall motion in the infarcted area. Coronary artery bypass surgery was performed only in the case of recurrent ischemia and triple-vessel disease, and always after completion of the isotopic studies required by the protocol of the study.
Left Ventricular Function
Left ventricular angiography was suitable for quantitative analysis in all 169 patients who were submitted to invasive procedures. No significant differences in left ventricular ejection fraction ( Figure 2 ) or dyssynergic score (Figure 3 ) appeared between the two treatment groups. Radionuclide angiography and single-photon emission computed tomography were performed on average on day 18+5 in the APSAC group and day 18+6 in the rt-PA group. Radionuclide angiography was available and suitable for analysis in 160 patients. The missing values were due to the death of 12 patients before the investigation, to the nonparticipation of some patients, and to the unavailability of gamma cameras or unsuitable acquisition of data for 11 patients. These missing values were equally distributed in both therapeutic groups. No significant differences appeared between the two treatment groups in terms of global (Figure 4) or regional ( Figure 5 ) wall motion at the predischarge isotopic analysis.
Infarct Size
The infarct size was not statistically significant between the two therapeutic groups ( Figure 6 ). A statistically significant difference appeared between the two treatment groups in the anterior wall infarction subgroup but not in the inferior wall infarction subgroup. A significant inverse relation between infarct size and left ventricular ejection fraction was found in the overall study group (y=-0.96x+57, r=-0.72; p<0.0001) as well as in each treatment group (y=-0.95x+57, r=-0.69; p<0.0001 in the APSAC group and y= -0.98x+56, r= -0.69; p<0.0001 in the rt-PA group).
Biological Data
No significant differences appeared in blood cell count or hemoglobin levels between the two groups at 24 hours. Creatine kinase values peaked at similar levels in both therapeutic groups. Fibrinogen levels decreased significantly in both groups, although the diminution was far more noticeable in the APSAC group than in the rt-PA group, where it remained on average above 2 g/l. In the APSAC group it averaged 0.65+ 1.01 g/l at 6 hours and 1.46+ 1.22 g/l at 24 hours (Figure 7) . The fibrinogen level decreased below 1 g/l in all but 14 APSAC-treated patients (15.5%). Conversely, it remained above 1 g/l in all but 16 rt-PA- tion. Yet up to now, the evaluation of each drug has been carried out only in distinct, though comparably designed, trials. Therefore, a direct comparison of the favorable and undesirable effects of each drug within a single clinical trial was needed to see whether any clear advantage of one drug over the other could be shown. This trial demonstrated that both drugs can be considered equally safe and effective on the end points studied. DThe bleeding complication rate was not significantly different between the two therapeutic groups: 11 out of 90 APSAC-treated patients (12.2%) and nine out of 93 rt-PA-treated patients (9.6%) suffered from bleeding. The hemorrhagic complication was benign in all but four patients, in whom life-threatening bleeding as previously defined occurred. These results are in agreement with the bleeding complication rate reported in previous large trials in which either =rtPA n -49 drug was used.8,21 However, according to the sample size of our trial, the minimal difference in bleeding complication rate that the statistical power of this 10 (17.2%) . In both therapeutic groups, there was a nonsignificant fall between pretreatment and posttreatment values in hemoglobin level, red blood cell count, and hematocrit.
The hemoglobin level fell more than 3 g/dl between the pretreatment state and the 24th hour in five APSAC patients (5.3%) and in three rt-PA patients (3.2%). Blood transfusion was required for one APSAC patient and two rt-PA patients.
Discussion APSAC and rt-PA have both been used extensively in the treatment of acute myocardial infarc- power to rule out a doubling of the overall bleeding complication rate with one drug compared with the other, it is not large enough to detect differences in rare events such as life-threatening hemorrhages. Only trials involving more than 1,000 patients have such a statistical power. The recently orally reported ISIS-3 trial in which more than 40,000 patients were enrolled failed to show any significant difference in the bleeding complication rate between APSACand rt-PA-treated patients. This was true for the overall bleeding complication rate as well as for the frequency of probable cerebral hemorrhage (unpublished data). This similar bleeding complication rate was observed with the currently recommended dose regimens for both thrombolytic agents as well as with the currently recommended adjunctive therapies (i.e., aspirin and heparin), heparin being administered from the beginning with rt-PA and at the fourth hour with APSAC. Moreover, this similar overall bleeding complication rate occurred despite a far different evolution of the fibrinogen level in both therapeutic groups. Depression of fibrinogen level below 1 g/l was observed in 84% of the APSAC patients as opposed to only 16% of the rt-PA patients, figures comparable with those previously reported with these two thrombolytic agents.7-16,22-24 Therefore, one can reasonably assume that deep depression of fibrinogen under thrombolytic therapy probably does not play a determining role in the occurrence of bleeding, although in two previous studies, the occurrence of bleeding under rt-PA was suspected to be linked to deep fibrinogen depression and ensuing increased levels of fibrinogen degradation products.22'23 However, according to Stump et a122 the relation of systemic fibrinogenolysis and bleeding, though significant, was weak. Moreover, the risk of bleeding was shown to be more closely related to the invasive procedure and to the demographic characteristics of the patient population, particularly older age, female gender, and low body weight.22 In their study group, intracranial hemorrhage was observed in two patients with very low body weight. Noteworthy in our own study is the fact that the only fatal intracranial hemorrhage occurred in an rt-PA patient who weighed only 48 kg. The total dose of rt-PA injected into this patient amounted to 2 mg/kg of her body weight. This can be far too much, since the bleeding complication rate with rt-PA has been shown to be dose related. 24 In trials where the total dose of rt-PA was increased to 150 mg, the occurrence of intracranial hemorrhages rose above 1%, so the protocol of these trials had to be modified and the total dose of rt-PA reduced to 100 mg, the presently recommended dose. 25, 26 The protocol of the present study was therefore modified in order to have a total dose far below 2 mg/kg of body weight. It remains to be determined whether therapeutic protocols adjusted to body weight can reduce the frequency of severe bleeding in high-risk patients.27
The frequency of hypotension was very similar in both groups. APSAC, a streptokinase-derived compound, has been shown in other trials to induce hypotensive reactions as frequently as streptokinase. In a randomized trial by Hogg et at28 using APSAC and streptokinase, hypotension, defined according to other criteria, was more frequent than in our study and was seen to have a similar frequency with both drugs. In the GISSI-2 trial,21 hypotension occurred more frequently with streptokinase than with rt-PA. In the ISIS-3 study, the frequency of hypotension was identical in streptokinaseand APSAC-treated patients (6.8% versus 7.2%) but was significantly lower in rt-PA-treated patients (4.3%) (unpublished data). For all these reasons, we could have expected a higher frequency of hypotension in the APSAC group than in the rt-PA group. Surprisingly, the frequency of hypotension was not significantly different with both drugs. However, the minimal difference in the frequency of hypotensive reactions that the statistical power of our trial allows to be reported as statistically significant is 14%, figures far beyond the observed differences. In fact, the hypotensive effect of a drug cannot always be differentiated from the spontaneous hypotension that frequently occurs during the early stage of acute myocardial infarction, particularly when the inferior wall is involved.
Except in one case of vasculitis, a known rare consequence of the use of APSAC29 that occurred in only one patient, no allergic reactions clearly attributable to APSAC were observed. Allergic rashes and chills were equally distributed in both therapeutic groups.
Efficacy
The efficacy was identical in both therapeutic groups regardless of the end point under consideration.
The global and regional left ventricular systolic function and infarct size were equivalent in both groups. With regard to the design of the trial, one can assume that there is less than a 10% chance that a difference of 0.05 or more for left ventricular ejection fraction, 3.5 or more for asynergic score, and 5% or more for infarct size would actually exist between the two therapeutic groups. Given the difference in left ventricular ejection fraction observed in our trial, a sample size of 1,200 patients would have been required to ensure that the difference was statistically significant without demonstrating that the observed difference was clinically relevant. In admitting that infarct size and residual left ventricular function were the strongest determinants of outcome in myocardial infarction, we had anticipated, given the results of our trial (which were available before the results of ISIS-3 were reported), that the ISIS-3 study would probably fail to demonstrate any difference of mortality rate in APSACand rt-PA-treated patients. This was confirmed by the recently reported data of this megatrial.
A tendency toward a smaller infarct size was observed in the anterior wall infarction group. However, the proximal left anterior descending artery was involved in the APSAC group more frequently than in the rt-PA group, implying that the mass of myocardium at risk was potentially larger in the former group, thus resulting in larger infarct size.
The patency rate was similar in both groups. It was not possible to have an exact idea of the early patency rate because the coronary angiography was performed only after the first 24 hours of evolution. The patency rate observed after 5 days is the result of reperfusion induced by thrombolytic therapy, spontaneous reperfusion, and secondary reocclusion. No precise conclusions on reocclusion rates can be drawn from this trial, but clinical reinfarction may give an indirect idea of the reocclusion rate in both therapeutic groups. Secondary reocclusion is the Achilles' heel of thrombolytic therapy in acute myocardial infarction because its detrimental effects can partially or totally offset the myocardial salvage produced by early reperfusion. Various reocclusion rates have been published concerning the two drugs studied in this trial but they have always been extracted from pooled data.30 APSAC has been thought to produce very low reocclusion rates as a result of a prolonged thrombolytic state inducing a more complete thrombolysis at the site of occlusion. Conversely, the reocclusion rate with rt-PA has been estimated to be relatively high in comparison with APSAC because of its very short half-life. 30 In terms of clinical reinfarction rate, the data found in this trial do not favor this opinion. Equivalent reinfarction rates (under 10%) were observed in both therapeutic groups under similar drug regimens, including heparin and aspirin. With APSAC, the reocclusion rate studied closely in one specific trial was recently proved to be much lower than previously expected, with a frequency below 5% 7 days after the administration of APSAC.31
Limitations of the Study
Left ventricular contrast angiography and radionuclide angiography are two fully validated, widely practiced methods used to estimate global as well as regional wall motion of the left ventricle. Conversely, single-photon emission computed tomography has seldom been used in the past to estimate infarct size. Direct estimation of infarct size from single-photon emission computed tomography contains known limitations linked to the pharmacokinetics of thallium-201 in the normal and ischemic myocardium. Experimental data have shown that the size of myocardial defect varies over time and that very early measurements of thallium defect may lead to overestimations of infarct size.32 Full recovery of metabolism and function within the infarct zone may be delayed as long as 10-12 days after reperfusion.32 In the clinical field, serial studies have shown that defect size in reperfused patients decreases from measurements made within the first hours to those performed on the fourth day and even those performed in the sixth week.33 This phenomenon probably indicates that in these patients, some persistent defects are related not to an irreversibly damaged myocardium but rather to severe ischemia, and that recovery in the thallium uptake in the area of ischemia may still occur after several days. Therefore, to avoid any possible bias in estimating infarct size, it is recommended that the defect size be estimated long after reperfusion has occurred. The optimal timing to perform studies may well be the second week after the onset of symptoms. 32 In our study, infarct size was measured with Maublant and coworkers'20 original method developed and validated in animal models. This method has been shown to produce accurate measurements of infarct size in dogs. We used it in one previous clinical study to estimate the ability of APSAC to reduce infarct size. 16 This method allowed us to detect a 31% reduction of infarct size in the APSAC group compared with the heparin group. Furthermore, infarct size was closely and inversely correlated to left ventricular ejection fraction estimated from radionuclide angiography, thus confirming the validity of our method of determining infarct size. It is well worth noting that in trials where infarct size was assessed by the enzymatic release method, the magnitude of infarct size reduction under thrombolytic therapy was similar to that observed in our trial. 34 Ritchie et a135 also used single-photon emission computerized tomography to quantify infarct size in two clinical trials. In the first trial, which compared intracoronary streptokinase to conventional heparin, they failed to find any significant differences between the two therapeutic groups, but entry into the trial was allowed up to 12 hours after the onset of symptoms. In the second trial, which compared intravenous streptokinase with conventional therapy, they found a 21% reduction in infarct size in the streptokinase group, figures close to those found in our previous trial. 36 
Practical Considerations
The practical concept that emerges from this trial is that both drugs are equally efficient and safe in acute myocardial infarction at the dosage tested with the most commonly admitted adjunctive therapy. Given the easy applicability of APSAC in bolus injection compared with the 3-hour infusion necessary with rt-PA, APSAC may be a particularly suitable thrombolytic agent for emergency treatment in myocardial infarction, namely in prehospital thrombolysis. However, because of its antigenic effects, it cannot be readministered in the case of recurrent infarction because the appearance of antibodies noticeable from the fifth day of initial injection would preclude any thrombolytic activity of the drug in case of readministration.37
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